Abstract
413 Background: Treatment patterns and outcomes with first-line therapy for PSCC are unclear. We conducted a retrospective analysis of the NCDB to study this issue and evaluate prognostic factors in treated patients (pts). Methods: Data from the NCDB was obtained for pts diagnosed with clinical stage 4 PSCC from 1998-2011. The following variables were evaluated: age, Charlson Comorbidity Index (CCI), race, survival, socioeconomic status (SES) based on median income of area of residence and therapy. Treatment patterns were described. Multivariate analyses (MVA) were conducted to assess the impact of factors on survival of pts receiving therapy. Results: Of 14,395 pts with PSCC, 614 pts with stage 4 PSCC were evaluable with complete data. The mean age was 61.9 (range 22-90), 498 (81.1%) were white and 91 (14.8%) were black. 300 (48.7%) pts received no anti-cancer therapy, 245 (39.9%) received chemotherapy (+/- other therapy) and 69 (11.24%) received radiation (+/- non-chemotherapy agents). Pts in the chemotherapy group were significantly younger (mean age 58.8 years) than those in the radiation (63.5 years) or no therapy (64.1 years) group (p < 0.001), but there were no significant differences in other variables between the 3 groups. The median survival from date of therapy of those in the chemotherapy and radiation groups were 9.75 and 8.65 months, respectively. MVA of pts who received therapy showed that non-white race (p = 0.006) and shorter time from diagnosis to therapy (p = 0.005) were significantly associated with poor survival, while chemotherapy, SES, age and CCI did not impact survival. Additionally, non-white race showed a trend for association with poor survival (p = 0.089) in those not receiving anti-cancer therapy. Conclusions: A minority of pts (39.9%) with stage 4 PSCC received chemotherapy in this large NCDB cohort, who were younger than those who received radiation or no therapy. The association of non-white race with poor survival suggests the impact of germline factors and disparities in therapy. The absence of significant impact of chemotherapy on survival in this real world PSCC cohort highlights unmet needs in this orphan disease and the need for discovery of effective agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
